telisotuzumab vedodin
Trade name: Emrelis
mAbapprovedADC
Approved
May 14, 2025
Clinical trial activity
12 trials · 2 clinical orgs · 1 marketing orgs
Phase 1
5
Phase 2
6
Phase 3
2
Phase 4
0
Earliest trial started Oct 6, 2011 (NCT01472016)
Timeline
Indications
Approved for
Mechanism of action
- Hepatocyte growth factor receptorBINDING AGENT
Hepatocyte growth factor receptor binding agent
- Hepatocyte growth factor receptorINHIBITOR
MET inhibitor
- TubulinINHIBITOR
Tubulin inhibitor
Beta tubulin vinca binding domain
- Tubulin beta-4B chain (TUBB4B) ↗
- Tubulin beta-1 chain (TUBB1) ↗
- Tubulin alpha-3C chain (TUBA3C) ↗
- Tubulin alpha-4A chain (TUBA4A) ↗
- Tubulin beta-3 chain (TUBB3) ↗
- Tubulin alpha-1A chain (TUBA1A) ↗
- Tubulin beta-4A chain (TUBB4A) ↗
- Tubulin beta-8 chain (TUBB8) ↗
- Tubulin beta chain (TUBB) ↗
- Tubulin alpha-1B chain (TUBA1B) ↗
- Tubulin alpha-1C chain (TUBA1C) ↗
- Tubulin alpha-3E chain (TUBA3E) ↗
- Tubulin beta-2A chain (TUBB2A) ↗
- Tubulin beta-2B chain (TUBB2B) ↗
- Tubulin beta-6 chain (TUBB6) ↗
Approval history
- approvedPriority reviewMay 14, 2025
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
- Payload
- Monomethylauristatin E
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3990032 ↗
- ChEMBLCHEMBL3545419 ↗
Also known as
- abbv-399
- abt-700
- abt-700
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06977724 | Phase 1 | Aug 26, 2025 | AbbVie |
| NCT06568939 | Phase 2 | Jan 30, 2025 | AbbVie |
| NCT06093503 | Phase 3 | May 31, 2024 | AbbVie |
| NCT05513703 | Phase 2 | Nov 21, 2022 | AbbVie |
| NCT05512390 | Phase 1 | Aug 27, 2022 | AbbVie |
| NCT04928846 | Phase 3 | Dec 10, 2021 | AbbVie |
| NCT03539536 | Phase 2 | Sep 27, 2018 | AbbVie |
| NCT03574753 | Phase 2 | Feb 5, 2018 | Southwest Oncology Group |
| NCT03311477 | Phase 1 | Nov 6, 2017 | AbbVie |
| NCT02099058 | Phase 1 | Apr 9, 2014 | AbbVie |
| NCT01472016 | Phase 1 | Oct 6, 2011 | AbbVie |
| NCT04830202 | N/A | — | AbbVie |
Showing 12 of 12 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AbbVie | For profit | 11 | 11 | 4 | 2011 |
| Southwest Oncology Group | Academic/Hospital | 1 | 1 | 1 | 2018 |
2 organizations
Page 1 / 1
Marketing (1)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| AbbVie | For profit | MKTG | May 14, 2025 |